Since Quanam's product falls under the license agreement between Angiotech and Boston Scientific, it removes any intellectual property risk that may have existed prior to the acquisition. Boston Scientific's recent announcement to discontinue enrollment in Quanam's European studies was a result of protocol violations that occurred prior to Boston Scientific's acquisition of the company. This does not impact Angiotech's original product development timeline based on our original agreement in 1997. Results from this study will be available in early 2002. Thank you again for your support and we look forward to significant progress in the coming quarter.
All amounts are in Canadian dollars.
This increase reflected the full enrolment of patients in the Company's phase 2 clinical study for secondary progressive multiple sclerosis. This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the ability of the Company to implement its product development programs as well as its overall business strategy, competitive offerings, third party intellectual property rights and other factors described in the Company's filing with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.